Holen Sie sich die Stockscreener-App
12.21
0.00%
0.205
Neuropace Inc Aktie (NPCE) Neueste Nachrichten
NeuroPace Inc (NPCE): A New Perspective - Stocks Register
NeuroPace Shares Updates on Financial Performance and Board of Directors - Defense World
NeuroPace reports preliminary Q4 revenue - MSN
NeuroPace Sees Rise in 4Q, Full-Year Sales - MarketWatch
NeuroPace Strengthens Board and Reports Strong 2024 Results - TipRanks
NeuroPace Announces Preliminary Unaudited Revenue for Fourth Quarter and Full Year 2024 and Provides Business Updates - The Manila Times
NeuroPace narrows FY24 revenue view to $79.4M-$79.9M from $78M-$80M - TipRanks
Neuropace, Inc. Appoints Scott Huennekens to Its Board of Directors - Marketscreener.com
NeuroPace Inc (NPCE) Trading Down 5.31% on Jan 8 - GuruFocus.com
Institutions profited after NeuroPace, Inc.'s (NASDAQ:NPCE) market cap rose US$37m last week but private equity firms profited the most - Simply Wall St
NeuroPace, Inc. (NASDAQ:NPCE) Shares Bought by Barclays PLC - Defense World
Geode Capital Management LLC Has $2.21 Million Position in NeuroPace, Inc. (NASDAQ:NPCE) - Defense World
When the Price of (NPCE) Talks, People Listen - Stock Traders Daily
Head to Head Analysis: Minerva Surgical (NASDAQ:UTRS) & NeuroPace (NASDAQ:NPCE) - Defense World
State Street Corp Increases Stock Position in NeuroPace, Inc. (NASDAQ:NPCE) - Defense World
NeuroPace (NASDAQ:NPCE) versus NEXGEL (NASDAQ:NXGL) Head to Head Contrast - Defense World
NeuroPace (NPCE) Upgraded to Buy: What Does It Mean for the Stock? - Yahoo Finance
Brokerages Set NeuroPace, Inc. (NASDAQ:NPCE) Price Target at $14.50 - Defense World
NeuroPace, Inc. (NASDAQ:NPCE) Receives $14.50 Average PT from Analysts - MarketBeat
NeuroPace to Present at the 43rd Annual J.P. Morgan Healthcare Conference - The Manila Times
NeuroPace, Inc. to Present at 43rd Annual J.P. Morgan Healthcare Conference on January 15, 2025 - Nasdaq
NeuroPace to Present at J.P. Morgan's Prestigious Healthcare Conference in January 2025 - StockTitan
NeuroPace (NASDAQ:NPCE) Trading Up 4% – Should You Buy? - Defense World
NeuroPace (NASDAQ:NPCE) Price Target Raised to $14.00 - MarketBeat
JPMorgan sees NeuroPace stock undervalued, highlights clinically superior RNS device - Investing.com
NeuroPace (NASDAQ:NPCE) Trading Up 4%Should You Buy? - MarketBeat
NeuroPace's SWOT analysis: epilepsy treatment innovator's stock poised for growth - Investing.com
Perspective Therapeutics (NYSE:CATX) vs. NeuroPace (NASDAQ:NPCE) Head to Head Contrast - Defense World
Neurostimulation Market is experiencing new opportunities & - openPR
NPCENeuropace, Inc. Latest Stock News & Market Updates - StockTitan
NeuroPace to Host Investor Day on January 28th in New York City - The Manila Times
NeuroPace, Inc. Announces Investor Day to Discuss RNS Technology and Future Plans on January 28, 2025 - Nasdaq
NeuroPace Sets Investor Day to Showcase RNS Technology and Growth Strategy in Epilepsy Treatment - StockTitan
Wall Street Analysts Think NeuroPace (NPCE) Could Surge 31.47%: Read This Before Placing a Bet - MSN
How To Trade (NPCE) - Stock Traders Daily
NeuroPace to Showcase the RNS System at the 2024 American Epilepsy Society (AES) Annual Meeting - The Manila Times
NeuroPace's RNS System Shows 82% Seizure Reduction, Featured in 70+ Studies at AES 2024 - StockTitan
After Leaping 90% NeuroPace, Inc. (NASDAQ:NPCE) Shares Are Not Flying Under The Radar - Simply Wall St
NeuroPace Completes Enrollment in Feasibility Study of RNS System for Lennox-Gastaut Syndrome - The Manila Times
NeuroPace Completes Groundbreaking Trial Enrollment for Severe Epilepsy Treatment Innovation - StockTitan
NeuroPace Inc (NPCE) Stock Price Up 7.36% on Dec 2 - GuruFocus.com
NeuroPace Inc (NPCE) Shares Up 3.41% on Nov 29 - GuruFocus.com
Brokerages Set NeuroPace, Inc. (NASDAQ:NPCE) PT at $14.60 - Defense World
NeuroPace's SWOT analysis: epilepsy device maker's stock poised for growth - Investing.com India
NeuroPace, Inc. (NASDAQ:NPCE) Receives $14.60 Average PT from Analysts - MarketBeat
NeuroPace, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Top 10 Deep Brain Stimulation Device Companies | Provides Best DevicesMarket.us Media - Market.us Media - United States Market News
NeuroPace (NASDAQ:NPCE) versus Cerus (NASDAQ:CERS) Financial Analysis - Defense World
NeuroPace, Inc. (NPCE) Reports Q3 Loss, Tops Revenue Estimates - MSN
What Makes NeuroPace (NPCE) a New Buy Stock - MSN
Wall Street Analysts Believe NeuroPace (NPCE) Could Rally 54.34%: Here's is How to Trade - Yahoo Finance
1.96%
2.88%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):